Αποτελέσματα Αναζήτησης
New oral anticoagulants include direct inhibitors of thrombin, factor Xa and factor IXa. Designed to provide more streamlined anticoagulation than warfarin, these agents can be given without routine coagulation monitoring.
4 Μαρ 2020 · Antiplatelet agents and anticoagulants are a mainstay for the prevention and treatment of thrombosis. However, despite advances in antithrombotic therapy, a fundamental challenge is the side...
31 Αυγ 2023 · In the past 15 years, anticoagulant therapy for VTE has been simplified with the introduction of direct oral anticoagulants (DOACs). 3, 4 These agents include apixaban, edoxaban, and rivaroxaban, which inhibit FX (factor X) a, and dabigatran, which inhibits thrombin. Of the DOACs, the oral FXa inhibitors are the most widely used.
12 Οκτ 2020 · Clinical evaluation of new anticoagulants often starts in patients undergoing joint replacement surgery because such patients are at high risk of postoperative venous thromboembolism, particularly asymptomatic deep vein thrombosis (DVT), which can be detected on routine venography.
19 Μαρ 2015 · The non-vitamin K antagonist oral anticoagulants are already replacing low-molecular-weight heparin for thromboprophylaxis in patients undergoing elective hip or knee arthroplasty and replacing warfarin for stroke prevention in patients with atrial fibrillation and treatment of venous thromboembolism.
With the goal of developing a new class of anticoagulants associated with a lower risk of bleeding than currently available agents, dozens of drugs targeting the contact system are now in development.
Historically, vitamin K antagonists such as warfarin were the mainstay of anticoagulant therapy, prized for their effectiveness in a broad range of thromboembolic conditions. The emergence of direct oral anticoagulants (DOAC) since 2010 has marked a significant shift in this landscape.
